Inflammatory mediator in epidermal keratinocyte

The entry "Inflammatory mediators in epidermal keratinocytes" does **not** refer to a single, specific molecular target or receptor. Instead, it describes a broad class of molecules—such as cytokines (e.g., IL‑1β, TNF‑α), chemokines (e.g., CCL2/MCP‑1, CXCL10/IP‑10), and antimicrobial peptides—that are produced by **epidermal keratinocytes** in response to injury, infection, or immune stimuli[1][2][3][4][6][8]. These mediators play critical roles in orchestrating the skin’s immune responses by recruiting and activating various immune cells (T cells, dendritic cells) and modulating inflammation. Keratinocytes themselves are not therapeutic targets; rather, they are effector cells that release these mediators as part of complex inflammatory networks involved in diseases such as atopic dermatitis and psoriasis[1][3]. Because this term refers to a functional group of molecules rather than a defined protein or receptor entity—and encompasses many different pathways—it is not considered an individual therapeutic target. Therefore: > The designation "Inflammatory mediators in epidermal keratinocytes" is too broad for structured drug-target mapping; it should be replaced with the specific mediator(s) of interest (e.g., "Interleukin 1 beta," "Tumor necrosis factor alpha," etc.) for accurate data structuring. If you need information on any particular inflammatory mediator produced by keratinocytes—such as IL‑1β, TNF‑α, CCL20—or on receptors expressed by these cells (like TRPV1 or IL‑31RA), please specify so detailed structured information can be provided[5][6].